MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Monopar Therapeutics
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$71.47+2.20 (+3.18%)
Close on Oct 19, 2026
- Market cap
- $610.53M
- P/E (TTM)
- –
- Dividend yield
- –